Digital healthcare company, Vivante Health, has announced the closing of $31 million in Series B funding to develop its platform focused on the management of digestive conditions.
The latest investment was led by new investor Mercato Partners, and brings the total capital raised by Vivante to date to $47 million, following a $16 million Series A round in late 2021.
The new funding also comes on the heels of recent enhancements to the company’s proprietary GIThrive platform, which provides care for a range of digestive diseases from common yet often debilitating disorders such as IBS and GERD, to complex conditions such as Inflammatory Bowel Disease which requires high levels of care coordination.
GIThrive allows users to log food and symptoms, as well as offering online educational resources, 24/7 access to experts and AI-driven personalised care plans. It also offers access to a nationwide network of internists and gastroenterologists for diagnosis, treatment, lab test orders and prescriptions, alongside other new services designed to bridge the gap between virtual and real-world care.
According to Vivante, more than 90 per cent of GIThrive users report that the platform’s digital resources and 24/7 human support help relieve digestive symptoms and improve their quality of life.
Employers that have adopted GIThrive are said to have seen decreases of 15 per cent or more in digestive-related healthcare spend due to increased medication adherence and behaviour modification that reduce emergency room visits and inpatient admissions.
The Series B capital is intended to support continued technology upgrades designed to predict the onset and progression of GI conditions and provide complete virtual care for digestive disorders.
It will also be applied to ongoing expansion of the company’s commercial and client support teams along with onboarding support for new employers, health plans, and channel partners seeking better solutions for reducing the personal and financial toll of digestive disease.
The round also includes new capital from Health Catalyst Capital as well as returning investors 7wireVentures, Intermountain Ventures, Distributed Ventures, Human Capital, and SemperVirens.
Bill Snyder, Vivante Health CEO, commented: “We are thrilled to have the support of industry-leading capital partners as we execute on our vision at Vivante.
“One in four Americans suffers from a digestive disorder or undiagnosed digestive symptoms that affect their quality of life as well as their healthcare costs. We have proven that our scalable technology platform paired with our comprehensive care team results in better health, lower costs, and a much better experience for the members we serve.”
Joe Kaiser, managing director at Mercato Partners, added: “Vivante is reinventing the management of chronic gut conditions through its ‘right care at the right time’ triage methodology. This approach to patient-centric, digital GI management bridges the gap that exists between generalist and specialist care, giving patients back time, money, and quality of life lost to gastrointestinal issues as well as delivering a compelling ROI to employers.”
